��������

Christopher de Souza, Ph.D., shares responsibility for the day-to-day operations of Broadview Ventures, including business development strategy, identification, and screening of new investment opportunities, negotiation of partnering terms and deal structure, as well as portfolio company board involvement. He leverages 20 years of experience in biopharmaceutical R&D, business development, and corporate strategy to help meet Broadview Ventures' mission.

Christopher started his pharmaceutical career at Novartis where he was a senior scientist in the Metabolic and Cardiovascular Diseases group and then Director of Strategic Alliances with responsibilities for the therapeutic area strategy, business development, and alliance management. After Novartis, Christopher was VP of Business Development at SkyePharma US Inc, a drug delivery company, where he was responsible for out-licensing SkyePharma’s clinical assets and drug delivery technologies. Christopher also founded a business development consulting practice with several clients including JSB-Partners, Diagnostics For All, and Metaome.

Christopher received an MBA from Rutgers University and a Ph.D. in physiology from Louisiana State University. He completed his post-doctoral training at “The Upjohn Company” and the Joslin Diabetes Center/Harvard Medical School.

Christopher currently serves as the board observer for Acesion, Allosteros, CellAegis, DecImmune, Gila Therapeutics, GI Windows, Intravascular Imaging Inc., Laurantis, Pulmokine, and VentriNova.